SSA
AGRX

Schonfeld Strategic Advisors’s Agile Therapeutics AGRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-445
Closed -$2.22M – 1633
2019
Q4 		$2.22M Buy
+445
New +$1.55M 0.05% 322

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's AGRX Position: Q1 2020 in Review

Schonfeld Strategic Advisors sold out of Agile Therapeutics (AGRX) in Q1 2020, closing a stake of 445 shares — an estimated $2.22M sold.

Schonfeld Strategic Advisors first reported a position in AGRX in Q4 2019 and held it in 1 quarter. The position peaked at $2.22M in Q4 2019. 61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

  • Schonfeld Strategic Advisors reported no remaining Agile Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 445 Agile Therapeutics shares in Q1 2020, an estimated $2.22M.
  • Schonfeld Strategic Advisors first reported a position in Agile Therapeutics in Q4 2019 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Agile Therapeutics position peaked at $2.22M in Q4 2019.
  • 61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2020, filed 15 May 2020.